Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 7/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.43 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.42 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.42 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.42 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.41 |
| ▸ | CLK1 | P49759 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.41 |
| ▸ | NQO2 | P16083 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | THRA | P10827 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29956684 | 1.00 | ERN1 (0.44) | ERN1CYP1A2ESR1ESR2TRIM24 | |
| SCHEMBL9669003 | 0.85 | MCL1 (0.49) | ERN1CYP1A2ESR1ESR2TRIM24 | |
| SCHEMBL9097166 | 0.84 | ESR1 (0.48) | ERN1CYP1A2ESR1ESR2TRIM24 | |
| SCHEMBL30365636 | 0.81 | CYP1A2 (0.43) | CYP1A2ESR1ESR2HSD17B1HSD17B2 | |
| SCHEMBL1506789 | 0.81 | CYP1A2 (0.43) | CYP1A2ESR1ESR2HSD17B1HSD17B2 | |
| SCHEMBL28189143 | 0.81 | CYP1A2 (0.46) | ERN1CYP1A2ESR1ESR2CLK1 | |
| SCHEMBL19066454 | 0.80 | ESR1 (0.41) | ERN1ESR1ESR2TRIM24TRIM33 | |
| Hydrochloric Acid SCHEMBL11130190 | 0.79 | ESR1 (0.44) | CYP1A2ESR1ESR2HSD17B1HSD17B2 | |
| SCHEMBL11903615 | 0.78 | ERN1 (0.50) | ERN1ESR1ESR2TRIM24TRIM33 | |
| SCHEMBL29953364 | 0.78 | NQO2 (0.55) | ERN1CYP1A2ESR1ESR2TRIM24 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106631980-B | A kind of water-soluble biological thiol two-photon fluorescence probe and its preparation method and application | 济南大学 | 2019-01-25 | — | — | CN | claimed |
| US-7265146-B2 | Integrin receptor inhibitors | GENENTECH, INC. (US) | 2007-09-04 | — | — | US | claimed |
| US-20050187284-A1 | Integrin receptor inhibitors | GENENTECH, INC. (US) | 2005-08-25 | — | — | US | claimed |
| EP-1330430-A2 | INTEGRIN RECEPTOR INHIBITORS | GENENTECH, INC. (US) | 2003-07-30 | — | — | EP | claimed |
| US-20020035104-A1 | Integrin receptor inhibitors | GENENTECH, INC. | 2002-03-21 | — | — | US | claimed |
| WO-2002016313-A2 | INTEGRIN RECEPTOR INHIBITORS | GENENTECH, INC. (US) | 2002-02-28 | — | — | WO | claimed |
| WO-1993004127-A1 | PROCESS FOR FORMING IMPROVED LIQUID CRYSTALLINE POLYMER BLENDS | HOECHST CELANESE CORPORATION (US) | 1993-03-04 | — | — | WO | claimed |
| EP-0375036-A1 | Thermotropic liquid-crystalline aromatic copolymers | ENICHEM S.p.A. (IT) | 1990-06-27 | — | — | EP | claimed |
| EP-4745634-A1 | COMPOSITION, OPTICALLY ANISOTROPIC FILM, AND COMPOUND | FUJIFILM Corporation (JP) | 2026-05-20 | — | — | EP | disclosed |
| US-20260092215-A1 | COMPOSITION, OPTICALLY ANISOTROPIC FILM, AND COMPOUND | FUJIFILM CORPORATION (JP) | 2026-04-02 | — | — | US | disclosed |
| WO-2025013902-A1 | COMPOSITION, OPTICALLY ANISOTROPIC FILM, AND COMPOUND | 富士フイルム株式会社 | 2025-01-16 | — | — | WO | disclosed |
| CN-109415304-B | Method for producing iron complex and method for producing ester compound using iron complex | 株式会社可乐丽 | 2022-07-22 | — | — | CN | disclosed |
| CN-111072650-B | Benzothiazole hydrogen sulfide fluorescent probe | 北京工商大学 | 2021-04-06 | — | — | CN | disclosed |
| CN-110551065-B | Deuterated Lucistanib compound and application thereof | 海创药业股份有限公司 | 2021-02-26 | — | — | CN | disclosed |
| EP-0375036-A1 | Thermotropic liquid-crystalline aromatic copolymers | ENICHEM S.p.A. (IT) | 1990-06-27 | — | — | EP | disclosed |
| EP-0166830-B1 | NON-WOVEN ARTICLES COMPRISED OF THERMOTROPIC LIQUID CRYSTAL POLYMER FIBERS AND METHOD OF PRODUCTION THEREOF | CELANESE CORPORATION (US) | 1989-10-04 | — | — | EP | disclosed |
| US-4864021-A | ANTICARCINOGENIC AGENTS, ANTITUMOR AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-09-05 | — | — | US | disclosed |
| EP-0323441-A2 | 5-Fluorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-07-05 | — | — | EP | disclosed |
| EP-0180897-A2 | 5-Fluorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-14 | — | — | EP | disclosed |
| EP-0180188-A2 | A composition for increasing the anti-cancer activity of an anti-cancer compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035104-A1 | Integrin receptor inhibitors | ITGB1, ITGA1, ITGA4 | ERN1 3237/4885CYP1A2 3743/4885ESR1 1516/4885 |
| US-20050187284-A1 | Integrin receptor inhibitors | ITGA4, ITGB4, ITGB1 | ERN1 4129/4885CYP1A2 3720/4885ESR1 1137/4885 |
| US-20260092215-A1 | COMPOSITION, OPTICALLY ANISOTROPIC FILM, AND COMPOUND | SMC1A, SMC2, SMC3 | ERN1 2602/4885CYP1A2 2993/4885ESR1 1651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.